Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 50, Issue 15, Pages 3743-3746Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm070269u
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA023168, R01 CA34619, R01 CA034619-19, R01 CA034619-17, R01 CA034619, R01 CA034619-18A1, P30 CA23168] Funding Source: Medline
Ask authors/readers for more resources
A gemcitabine (2',2'-difluorodeoxycytidine, dFdC) phosphoramidate prodrug designed for the intracellular delivery of gemcitabine 5'-monophosphate was synthesized. The prodrug was about an order of magnitude less active than gemcitabine against wild-type cells, and the nucleoside transport inhibitor dipyridamole reduced prodrug activity. The prodrug was more active than gemcitabine against two deoxycytidine kinase-deficient cell lines. The results suggest that the prodrug is a potent growth inhibitor that can bypass dCK deficiency at higher drug concentrations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available